SRT 2104

SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD+ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease[1][2][3].

Product Specifications

CAS Number

[1093403-33-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Sirtuin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/SRT-2104.html

Purity

99.27

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

O=C(C1=C(C)N=C(C2=CC=CN=C2)S1)NC3=CC=CC=C3C4=CN5C(SC=C5CN6CCOCC6)=N4

Molecular Formula

C26H24N6O2S2

Molecular Weight

516.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Hoffmann E, et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man.|[2]Jiao D, et al. MicroRNA-34a targets sirtuin 1 and leads to diabetes-induced testicular apoptotic cell death. J Mol Med (Berl) . 2018 Sep;96 (9) :939-949.|[3]Jiang M, et al. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1 (12) :1047-52.